Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Bon Health vs Maves

Bon Health
Graded #93

Lower grade

vs+0.3999999999999915
Maves
Graded #88

Higher grade

The verdict

Maves takes it — 71.8/100 to 71.4/100, but only just.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with… Bon Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +26
58
84
Dose & formulationBon Health +12
77
65
Clinical oversightBon Health +9
85
76
Labs & monitoringBon Health +13
65
52
FulfillmentBon Health +1
88
87
Contract termsMaves +2
53
55
Bon Health · left barMaves · right bar

The numbers

MetricBon HealthMaves
WeighScore71.4/10071.8/100
GradeCC
Scorecard rank#93#88
Semaglutide$170/mo (annual plan, compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$170/mo (annual plan, compounded)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Bon Health

Graded #93 · C

Strengths

  • Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
  • Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
  • 24/7 physician support included free with your order; 1-3 day rapid dispatch
  • Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered

Where it loses points

  • Best rates require a 6- or 12-month commitment ($170-195/mo); month-to-month is $330/mo
  • Doesn't name its specific compounding pharmacy
  • No legal entity name or LegitScript certification shown on the site
  • Compounded GLP-1s are not FDA-approved (the site discloses this)
Maves

Graded #88 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard